May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Cyclopentenylcytosine (CPE-C) Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model
Author Affiliations & Notes
  • E. G. Romanowski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • K. A. Yates
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • Y. J. Gordon
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • Footnotes
    Commercial Relationships  E.G. Romanowski, None; K.A. Yates, None; Y.J. Gordon, None.
  • Footnotes
    Support  NIH Grant EY05323 (YJG), NIH Core Grant EY08098 (OVSRC), Eye & Ear Foundation of Pittsburgh, RPB.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 824. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. G. Romanowski, K. A. Yates, Y. J. Gordon; Cyclopentenylcytosine (CPE-C) Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):824. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Presently, there is no FDA approved antiviral therapy for the treatment of adenovirus (Ad) ocular infections. The goal of the current study was to determine the antiviral efficacy of topical Cyclopentenylcytosine (CPE-C), a nucleoside analog of cytosine, on acute Ad replication in the Ad5/NZW rabbit ocular model.

 
Methods:
 

40 NZW rabbits were topically inoculated in both eyes, following corneal scarification, with 1.5 x 106 pfu/eye of Ad5. On day 1, the rabbits were divided into 4 topical treatment groups (n=10/group): I - 3% CPE-C, QID x 7 days; II - 3% CPE-C, BID x 7 days; III - 0.5% Cidofovir (CDV), BID x 7 days; IV - Control (saline), QID x 7 days. Both eyes of the rabbits were similarly treated. All eyes were cultured for virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14.

 
Results:
 

* p ≤ 0.011 compared to the Control.Topical 3% CPE-C four times daily and twice daily and 0.5% Cidofovir twice daily were significantly more effective than the Control in reducing Ad5 Positive Cultures/Total (Days 1-14), Duration of Ad5 Shedding, Mean Ad5 Titer (Days 1-5), and Mean Ad5 Titer (Days 7-14) in the Ad5/NZW rabbit ocular model. There were no significant differences between the two topical regimens of 3% CPE-C and both were as effective as the positive antiviral control, 0.5% Cidofovir.  

 
Conclusions:
 

CPE-C demonstrated potent anti-adenoviral activity in the Ad5/NZW rabbit ocular model. Additional studies are warranted to establish the clinical potential of CPE-C as a topical antiviral treatment for adenovirus ocular infections.

 
Keywords: adenovirus • antiviral drugs • conjunctivitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×